Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 1, 2020
Daily News
July 1, 2020
- LDP Generic Study Group Urges Govt to Restructure Drug Supply Chain
July 1, 2020
- 26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
July 1, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”
July 1, 2020
- Generic Use Rate at 76.9% in FY2019, 78.5% in Jan.-March 2020: JGA
July 1, 2020
- Chugai Files Polatuzumab Vedotin for DLBCL in Japan
July 1, 2020
- LDP Study Group Calls for Budgets to Accelerate Genome Analysis Project
July 1, 2020
- Otsuka, Axcelead Link Up for Drug Discovery in CNS Field
July 1, 2020
- Nichi-Iko to Suspend Supply of Olmesartan OD Tab. 20 mg as COVID-19 Cripples API Procurement
July 1, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…